Opinion|Videos|April 18, 2025
Population Outcomes and Return on Value With CGMs
Experts discuss the metrics used to evaluate continuous glucose monitoring (CGM)'s comprehensive return on investment, including both cost savings and quality measure performance, and identify which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, along with how these groups are prioritized for CGM access.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What metrics do you use to evaluate CGM's comprehensive return on investment, including both cost savings and quality measure performance?
- Which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, and how do you prioritize these groups for CGM access?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
3
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5